Effect of Doxofylline Combined with Budesonide in the Treatment of Elderly Patients with Chronic Obstructive Pulmonary Disease
YU Luan
Abstract:Objective:To explore the effect of Doxofylline combined with Budesonide in the treatment of elderly patients with chronic obstructive pulmonary disease(COPD).Method:A total of 100 elderly patients with COPD who admitted to Liupanshui People's Hospital from January to December 2023 were selected as the research objects,they were divided into the observation group(n=50,Doxofylline combined with Budesonide treatment)and the control group(n=50,Budesonide treatment)according to the random number table method.The lung function[forced vital capacity(FVC),forced expiratory volume in one second(FEV1),peak expiratory flow(PEF)],blood gas indexes[oxygen saturation(SaO2),partial pressure of oxygen(PaO2),partial pressure of carbon dioxide(PaCO2)],respiratory mechanics indexes[dynamic lung compliance(Cdyn),peak airway pressure(PIP),airway resistance(Raw)],quality of life and adverse reactions were compared between two groups.Result:The FEV1,FVC,PEF,SaO2,PaO2,Cdyn and generic quality of life inventory-74(GQOLI-74)scores of the observation group after treatment were higher than those of the control group,and PaCO2,Raw and PIP were lower than those of the control group,the differences were statistically significant(P<0.05);there was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:Doxofylline combined with Budesonide in the treatment of elderly patients with COPD can improve lung function,regulate blood gas indexes,improve respiratory mechanics indexes and quality of life,with few adverse reactions.
Keywords:Chronic obstructive pulmonary diseaseDoxofyllineBudesonideLung function
Publication Date:2025-03-15
Online Publishing Date:2025-08-15(First online date of this platform, not the publication date of the document)
Pages:4( 50-53 )
Chinese and Foreign Medical Research

Chinese and Foreign Medical Research

ISSN:1674-6805
Year, Vol.(Issue):2025,23(8)